Search
Displaying 121–130 of 532 for “Retinitis pigmentosa”
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
Research NewsIn a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Research NewsFrancois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
Why Genetic Testing is Important
An Overview of Genetic Testing for Inherited Retinal Degenerative Diseases
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
Research NewsReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
Research NewsOn September 4, 2018, seven researchers, including six previously funded by the Foundation, were recognized with the prestigious 2018 Antonio Champalimaud Vision Award for their contributions to the advancement of blindness-reversing RPE65 gene therapies.
-
Ophthotech is Advancing an Impressive Portfolio of Cutting-Edge Therapies for Retinal Diseases
Research NewsThe company is taking on a multi-track strategy that includes retinal gene-therapy development, including delivery of over-sized genes and design of a two-step process of gene knockdown and replacement for autosomal dominant conditions.
-
FFB Funding More than $2 Million in New Research
Research NewsSeventy scientists submitted requests for funding.
-
Persevering to Success with the Support of Family, Friends, and Faith
Beacon StoriesA story about living with retinitis pigmentosa.
-
French Gene Therapy Company Advancing Three Programs for Retinal Diseases
Research NewsHorama’s gene therapies are injections of healthy copies of a gene underneath the retina to compensate for the defective gene.
